Thanks for this. Looks very positiv. Its a win win study. No or low cost for ARIAD. Low risks for the doctors. Possible great reputation for the hospital and the doctors. Possible help for patients fully therapied, with no other view of help. Practical use of the wide spread genetic targets for ponatinib proven by scientific studies. Clinical study at wide spread cancer types. High hope for success of impact by Ponatinib.
Short runtime of the study. => Quick response of data for a much bigger market for Ponatinib!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.